NCT03916783 is a NA clinical trial of Combination intervention in HIV/AIDS, sponsored by Washington University School of Medicine.

Who is sponsoring NCT03916783?

NCT03916783 is sponsored by Washington University School of Medicine.

What drugs are being tested in NCT03916783?

Interventions in NCT03916783: Combination intervention.

What condition does NCT03916783 study?

NCT03916783 studies HIV/AIDS, Cancer.

Is NCT03916783 still recruiting?

NCT03916783 is currently withdrawn. Last updated 27 February 2025.

Last reviewed 2025-02-27 · How we verify

NCT03916783

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Suubi4Cancer: Improving Access to Pediatric Cancer Services and Treatment Adherence Among Children Living With HIV/AIDS

Withdrawn NA Last updated 27 February 2025

What this trial tests

NA trial testing Combination intervention in HIV/AIDS. Withdrawn.

Timeline

15 October 2020

Primary endpoint
20 September 2021

20 September 2021

Quick facts

Lead sponsor	Washington University School of Medicine
Phase	NA
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	supportive care
Start date	15 October 2020
Primary completion	20 September 2021
Estimated completion	20 September 2021
Sites	1 location across Uganda

Drugs / interventions tested

Combination intervention

Conditions studied

HIV/AIDS — all drugs for HIV/AIDS →
Cancer — all drugs for Cancer →

Sponsor

Washington University School of Medicine

Who can join

Adults 10 to 24, any sex, with HIV/AIDS or Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will tailor and explore the short-term preliminary outcomes of an existing evidence-based Economic Empowerment (EE) Intervention, Suubi (Hope in Luganda -local Ugandan language), on access to pediatric cancer diagnosis, care, and treatment adherence among youth living with HIV (YLWHIV) with suspected cancers. The study will specifically address the following aims/research questions: Aim 1. Identify confirmed and suspected cancer cases in a cohort of \>3000 HIV+ youth (ages 10-24) seen at 39 clinics in 5 districts heavily affected by HIV/AIDS in southern Uganda. Aim 2. Identify those lost to follow-up from the cohort in Aim 1 and determine reasons for loss to follow-up through qualitative interviews. 2.1. Identify those who have not returned to the clinic in ≥ 60 days (\~2 months) from their expected return visit date. 2.2. Determine reasons for loss to follow-up or death. Aim 3. Conduct an open clinical trial to establish the feasibility and acceptability of the Suubi4Cancer intervention. \*Due to insufficient sample size, Aim 3 is not implemented.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Suubi4Cancer: A protocol for an innovative combination intervention to improve access to pediatric cancer services and treatment adherence among children living with HIV/AIDS in Uganda.
Ssewamala FM, Sensoy Bahar O, Johnson KJ, Katumba RGN. · · 2019 · PMID 31650077 · DOI 10.1016/j.conctc.2019.100459

Verify or expand the search:

Other recruiting trials for HIV/AIDS

Currently open trials in the same condition.

NCT06741618 — MyPEEPS Mobile Plus: A Multi-Level HIV Prevention Intervention for Young MSM · NA · recruiting
NCT07298785 — Peer-led Dynamic Choice HIV Prevention for Women: The Peer-led DCP Pilot Study · NA · recruiting
NCT07072481 — Sustaining Innovative Tools to Expand Youth-Friendly HIV Self-Testing · NA · recruiting
NCT07064785 — Video-Intervention to Inspire Treatment Adherence for Life for Adolescents · NA · recruiting
NCT07074899 — Evaluation of a Multi-Component Intervention to Support HIV Testing and Linkage to Services Among MSM in Peru · NA · active not recruiting

Other Washington University School of Medicine trials

Trials by the same sponsor.

NCT05521997 — Glutaminase Inhibition and Chemoradiation in Advanced Cervical Cancer · Phase 2 · not yet recruiting
NCT07101666 — Total Neoadjuvant Therapy With Short Course Radiation Therapy in Gastric Cancer · Phase 2 · not yet recruiting
NCT07200089 — Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel) · Phase 1 · not yet recruiting
NCT07313592 — Whole Genome Sequencing (ChromoSeq®) for Acute Lymphoblastic Leukemia (ALL) Patients · not yet recruiting
NCT07419464 — 5-Fluorouracil Response and Optimization STudy (The FROST Trial) · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03916783 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Washington University School of Medicine
Last refreshed: 27 February 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03916783.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing